Quantcast
Last updated on April 19, 2014 at 8:29 EDT

Latest Hadasit Bio-Holdings Ltd. Stories

2012-01-18 09:30:00

NEW YORK, Jan. 18, 2012 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY) a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced the completion of an investment round totaling $1.4 million for Thrombotech Ltd. at a pre-investment valuation of $5 million. Thrombotech's three major shareholders participated in the round: Clal...

2011-12-01 09:00:00

NEW YORK, Dec. 1, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by the Hadassah University Hospital, Israel's foremost medical research center, announced that three more of its portfolio companies have received grant approvals from the Israeli Office of the Chief Scientist (OCS) in the Ministry of Industry, Trade and Labor. These approvals come in addition...

2011-11-07 10:23:00

NEW YORK, Nov. 7, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, and its subsidiary, BioMarCare Technologies Ltd. ("BioMarCare") announced that the Hospital's Ethics Committee has approved the use of up to 400 tissue biopsy samples in a retrospective clinical study. BioMarCare will use these...

2011-10-26 07:30:00

JERUSALEM, Oct. 26, 2011 /PRNewswire/ -- The following is a letter to shareholders from Ophir Shahaf, CEO of Hadasit Bio-Holdings, Ltd. (OTCBB: HADSY), a publicly traded portfolio of biotech companies based on intellectual property developed and owned by Hadassah University Hospital. Dear Fellow Investors, Hadasit Bio-Holdings is celebrating six years since its establishment by the Hadassah University Hospital and its IPO which made public participation in leading biotechnological...

2011-08-31 10:04:00

NEW YORK, Aug. 31, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, announced today that its CEO, Mr. Ophir Shahaf, will present at the Rodman & Renshaw Annual Global Investment Conference in New York City on Tuesday, September 13, 2011 at 12:05 p.m. ET. The conference will be held at the...

2011-08-17 08:52:00

NEW YORK, Aug. 17, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed by the Hadassah University Hospital, Israel's foremost medical research center, announced that its portfolio company Enlivex Therapeutics (92% owned by Hadasit Bio) has completed the recruitment of three out of four groups in its Phase I / II clinical trial using its treatment for the reduction of graft versus...

2011-08-03 09:45:00

NEW YORK, Aug. 3, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, and Clal Biotechnology Industries (TASE: CBI) announced a significant clinical advancement in their portfolio company, Thrombotech ( 24% and 42% ownership, respectively). The Company recently began its Phase IIa clinical trial...

2011-08-02 09:32:00

NEW YORK, Aug. 2, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, and its subsidiary, BioMarCare Technologies Ltd. ("BioMarCare") announced that the prestigious Binational Industrial Research and Development (BIRD) Foundation has given initial approval for a $900,000 grant for a joint project...

2011-06-27 10:43:00

NEW YORK, June 27, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, announced that it has listed and begun trading of American Depository Receipts (ADR) through BNY Mellon. Shares of the ADR launched on June 20, 2011 on the over-the-counter (OTC) market under the symbol HADSY. The Company's...